Haertter Sebastian
Drug Metabol Drug Interact. 2013;28(4):209-16. doi: 10.1515/dmdi-2013-0032.
The cytochrome P450 2D6 (CYP2D6) belongs to a group of CYPs considered of utmost importance in the metabolism of xenobiotics. Despite being of only minor abundance in the liver, it is involved in the clearance of >25% of marketed drugs. Accordingly, CYP2D6 can be very efficiently inhibited by a couple of commonly used drugs such as some antidepressants, although induction by any drug has not been observed thus far. CYP2D6 was also one of the first enzymes for which a highly polymorphic expression could be shown leading to a widespread range of functionality, from a complete lack of a functional enzyme to overexpression due to multiplication of active alleles. A clear relationship between the CYP2D6 genotype and adverse events during treatment with CNS-active drugs such as codeine, antidepressants, or antipsychotics could be demonstrated. More recently, some new aspects emerged about the potential endogenous function of CYP2D6 in terms of behavior and brain disorders.
细胞色素P450 2D6(CYP2D6)属于一组在异源物质代谢中被认为极为重要的细胞色素P450酶。尽管它在肝脏中的含量仅占少数,但却参与了超过25%的市售药物的清除。因此,CYP2D6可被一些常用药物(如某些抗抑郁药)非常有效地抑制,不过迄今为止尚未观察到任何药物对其有诱导作用。CYP2D6也是首批能显示出高度多态性表达的酶之一,这导致了广泛的功能范围,从完全缺乏功能性酶到由于活性等位基因倍增而导致的过表达。CYP2D6基因型与使用中枢神经系统活性药物(如可待因、抗抑郁药或抗精神病药)治疗期间的不良事件之间存在明确的关联。最近,在CYP2D6在行为和脑部疾病方面的潜在内源性功能方面出现了一些新情况。